Cost sharing and hereditary cancer risk: Predictors of willingness-to-pay for genetic testing. | 2012 ASCO Annual Meeting Abstracts

Cost sharing and hereditary cancer risk: Predictors of willingness-to-pay for genetic testing. | 2012 ASCO Annual Meeting Abstracts

Cost sharing and hereditary cancer risk: Predictors of willingness-to-pay for genetic testing.

Sub-category:
Cancer Genetics
Category:
Cancer Prevention/Epidemiology
Meeting:
2012 ASCO Annual Meeting
Abstract No:
1544
Citation:
J Clin Oncol 30, 2012 (suppl; abstr 1544) 

Author(s): Jennifer Madeline Matro, Karen Ruth, Yu-Ning Wong, Katen C. McCully, Christina Rybak, Michael J. Hall; Fox Chase Cancer Center, Philadelphia, PA

Abstract Disclosures

Abstract:
Background: The increasing availability of genetic testing (GT) in cancer (CA) care has been paralleled by increasing cost-sharing practices by payors that are intended to reduce overuse of health care services. Patients referred for hereditary CA risk assessment may be subject to financial deterrents such as high out-of-pocket (OOP) costs. Little is known about what factors may influence high-risk patients' willingness-to-pay (WTP) for GT. Methods: The Gastrointestinal (GI) Tumor Risk Assessment Registry includes individuals referred for evaluation of genetic CA risk based on personal and/or family hx. At enrollment, participants complete a survey collecting detailed demographic, CA hx, and psychosocial items related to CA risk. Baseline data on 406 participants were available; 21 who did not respond to WTP items were excluded. WTP items included intention for: GT only if paid by insurance; GT even if paid by self; and amount WTP (7 levels, $25 to $2000). Multivariable models examined predictors of WTP (self vs only if paid by insurance) (model 1, logistic), and predictors of amount WTP (model 2, ordinal logistic, 5 levels). All statistical tests are two-sided (α=0.05). Results: Most participants were women (73%), white (92%) and aged 45-64 (58%). 51% had ≥ 4 yr college degree; 22% had household income >$75,000; 42% had hx of GI CA; 56% had > 1 1^st degree relative (FDR) with colorectal CA (CRC). Overall, 82 (21.3%) were willing to have GT only if paid by insurance, and 303 (78.7%) were WTP OOP. Of those WTP, 271 (89%) stated an amount. Independent predictors of WTP (model 1) were: 1) expectation of positive result, 2) confidence to control CA risk, 3) fewer perceived barriers to CRC screening and 4) benefit of guiding screening (all p<0.05). Subjects WTP a higher amount (model 2) were male, more educated, and had greater CA worry, fewer FDR with CRC (all p<0.05), and more positive attitudes toward GT (p<0.01). Conclusions: Patients who are WTP some OOP costs for GT anticipate benefits to control of CA risk afforded by GT. Women and less educated patients may face greater barriers from high co-pays. Identifying patient-level factors associated with WTP for genetic services is increasingly important as GT is integrated into routine CA care.

 

  Other Abstracts in this Sub-Category:

	1. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the ASCO Quality Oncology Practice Initiative (QOPI). Meeting: 2012 ASCO Annual Meeting Abstract No: CRA1505 First Author: Marie Wood Category: Cancer Prevention/Epidemiology - Cancer Genetics
	2. Sensitivity of clinical BRCA1 testing compared with linkage analysis. Meeting: 2012 ASCO Annual Meeting Abstract No: 1506 First Author: Payal D. Shah Category: Cancer Prevention/Epidemiology - Cancer Genetics
	3. Use of PTEN protein dosage to predict for underlying germ-line PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes. Meeting: 2012 ASCO Annual Meeting Abstract No: 1508 First Author: Joanne Y. Y. Ngeow Category: Cancer Prevention/Epidemiology - Cancer Genetics